文献速递消化道肿瘤放疗姑息放疗与转移瘤

术前短程放化疗联合S-1/伊立替康治疗局部晚期低位直肠癌的I期试验(SHOWTIME研究)

The phase I trial of preoperative short-course chemoradiotherapy with S-1/irinotecan and short-course radiation in locally advanced lower rectal cancer (SHOWTIME study).
PubMed 文献 · Radiat Oncol · 2026-06-10

60 mg/m²时全部出现剂量限制性毒性,定为最大耐受剂量;50 mg/m²时6例中2例出现剂量限制性毒性,定为推荐剂量。推荐剂量的安全性和可行性得到证实,支持在全程新辅助治疗中进一步研究。

要点

  • 伊立替康推荐剂量为50 mg/m²,最大耐受剂量为60 mg/m²。
  • 最常见≥3级不良事件为腹泻。
  • 11例手术病例R0切除率100%,病理完全缓解率27.3%,降期率90.9%。

核心结论

  • 短程放化疗联合S-1/伊立替康(伊立替康50 mg/m²)的安全性和可行性得到证实,支持在直肠癌全程新辅助治疗中进一步研究。

主要发现

  • 60 mg/m²时全部患者出现剂量限制性毒性,定为最大耐受剂量;50 mg/m²时6例中2例出现剂量限制性毒性,定为推荐剂量。
  • 最常见≥3级不良事件为腹泻。
  • 全部患者完成短程放化疗方案,所有患者接受CapeOX为基础的巩固化疗。
  • 11例手术病例中R0切除率100%,病理完全缓解率27.3%,降期率90.9%。
  • 3例达到临床完全缓解并接受非手术治疗。

关键数值与推荐

  • 伊立替康最大耐受剂量为60 mg/m²,推荐剂量为50 mg/m²。
  • S-1第1-5天和第8-12天给药,伊立替康第1天和第8天给药。
  • 放疗总剂量25 Gy,分5次,第8-12天实施。

临床怎么用

  • 局部晚期直肠癌短程放化疗中伊立替康推荐剂量为50 mg/m²,需关注腹泻等不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A phase I study was conducted to determine the optimal dose of irinotecan in short-course chemoradiotherapy (SCCRT) using S-1/irinotecan and short-course radiotherapy (SCRT) for the development of a new total neoadjuvant therapy (TNT) regimen that is safe, effective, and has a low patient burden for locally advanced rectal cancer (LARC). METHODS: The objective of this study was to ascertain the maximum tolerated dose (MTD) and the recommended dose (RD) of irinotecan in SCCRT for locally advanced rectal cancer. The assessment of dose-limiting toxicity (DLT) was conducted over a 14-day period following treatment administration. The patient received a 14-day course of chemotherapy, with S-1 administered from the first to the fifth day and from the eighth to the twelfth day. Irinotecan was administered on the first and eighth days of treatment. The radiotherapy regimen was initiated with a total dose of 25 Gy, administered in five fractions from the eighth to twelfth day. RESULTS: Fifteen patients received SCRT in conjunction with S-1 and escalating doses of irinotecan (40-60 mg/m²). All patients completed the SCCRT protocol. At a dose of 60 mg/m², DLT occurred in all patients, thereby establishing this dosage as the MTD. At a dose of 50 mg/m², DLT was observed in two of six patients, thereby establishing this dose as the RD. The most prevalent Grade ≥ 3 adverse event was diarrhea. All patients received CapeOX-based consolidation chemotherapy. Among the 11 surgical cases, the R0 resection rate was 100%, with a pathological complete response in 27.3% and downstaging in 90.9%. Three patients demonstrated a complete clinical response and underwent non-operative management. CONCLUSION: The safety and feasibility of administering SCCRT with S-1/irinotecan at a 50 mg/m² irinotecan dose have been demonstrated. These findings support further investigation of this regimen in a TNT setting for rectal cancer. TRIAL REGISTRATION: The present study was duly registered with the Japan Clinical Trials Registry (jRCT s031210461). URL: https://jrct.mhlw.go.jp/re .

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Kojo K, Tanaka T, Yamanashi T, et al. The phase I trial of preoperative short-course chemoradiotherapy with S-1/irinotecan and short-course radiation in locally advanced lower rectal cancer (SHOWTIME study). Radiat Oncol. 2026. PMID: 42271445. doi:10.1186/s13014-026-02872-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。